The special expanded labeling grants patients access to a mechanism for evaluating the small intestine, a part of the bowel that cannot be reached by traditional upper endoscopy or colonoscopy, while eliminating the need for in-person interactions between clinicians and their patients.
The CapsoCam Plus video capsule system, which is manufactured by CapsoVision, Inc. and distributed exclusively in the United States and Canada by Pentax Medical, is the only self-contained capsule endoscopy system that does not require external equipment that must be worn by the patient.
Eligible patients swallow the device under supervision of a physician during a video call.
As the pill-sized device passes through the middle portion of the gastrointestinal tract, it captures 360-degree visualization of the duodenum, jejunum and ileum. The footage is later downloaded and placed on the cloud for physician review.
The CapsoCam Plus video capsule system is the only capsule endoscopy system on the market with 360° lateral viewing ability.
Importantly, the device contains its own light source and images are stored on the device, thus eliminating the need for patients to wear an external sensor belt or recording instrument.
This exclusive feature of the CapsoCam Plus video capsule system improves comfort, reduces associated costs, and increases ease of use.
After the capsule has passed through the system, a specialized retriever tool is used to collect the capsule, which is then packaged and shipped to a laboratory.
Once there, images are retrieved and loaded to the CapsoCloud, a HIPPA-compliant data management and storage system that connects to the CapsoView software interface for physician viewing and evaluation.
This FDA's Discretionary Enforcement Policy for Remote Digital Pathology Devices During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency was enacted to expand the availability of remote digital pathology devices that may help facilitate pathology services while reducing healthcare personnel contact and risk of potential exposure to COVID-19 through remote reviewing and reporting.
The policy is intended to remain in effect only for the duration of the public health emergency related to COVID-19 as declared by the Department of Health and Human Services.
Pentax Medical is a division of Hoya Group. Through R and D and manufacturing, Pentax Medical provides endoscopy solutions to the global medical community.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval